JWH 133 is a synthetic cannabinoid (CB) with Ki values of 3.4 nM and 677 nM for the peripheral CB2 receptor and central CB1 receptor, respectively[1].
JWH 133 inhibits tumor growth in mice, promoting apoptosis and destroying angiogenesis[2]. JWH 133 also inhibits inflammation of experimental colitis and pancreatitis in mice and in vitro models[3].
References:
[1]. Huffman J W, Liddle J, Yu S, et al. 3-(1',1'-Dimethylbutyl)-1-deoxy-Δ8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorganic & Medicinal Chemistry, 1999, 7: 2905-2914.
[2]. Casanova M L, Blázquez C, Martínez-Palacio J, et al. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. Journal of Clinical Investigation, 2003, 111(1): 43-50.
[3]. Kimball E S, Schneider C R, Wallace N H, et al. Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium. American Journal of Physiology and Gastrointestinal Liver Physiology, 2006, 291(2): G364-G371.
